Mercado cerrado

Biodesix, Inc. Common Stock BDSX

USD9,95

hoy

BDSX es la acción de Biodesix, Inc. Common Stock. Cotiza a USD 9,95. Puedes invertir en BDSX desde Chile con Racional, en dólares, sin comisión por transacción y desde CLP 5.000.

Invierte en Biodesix, Inc. Common Stock con Racional.

Racional te permite invertir en fondos indexados de bajo costo y +10.000 acciones de EE.UU. Comienza con solo CLP 5.000, en menos de 5 minutos.

Crear cuentaSúmate a más de 150.000 personas invirtiendo.

Descripción Biodesix, Inc. Common Stock

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Sitio web

AperturaUSD 10,06

Cierre previoUSD 9,79

Rango del díaUSD 9,85 – USD 11,32

Rango 52 sem.USD 5,46 – USD 30,60

Volumen0,4 M

Acciones en circulación10,6 M

CapitalizaciónUSD 109 M

Utilidad por acciónUSD -2,44

Empleados334

En bolsa desde2020

BDSX es la acción de Biodesix, Inc. Common Stock y cotiza en bolsa desde 2020. Su rentabilidad es de +25,89% en el último año, −58,55% en el último mes y +1,58% hoy. Datos al 15 de noviembre de 2026.

Rentabilidad por período

PeríodoBDSX

1 día

MTD

1 mes

YTD

1 año

Resultados financieros

Ingresos 2025

USD 88,5 M

Utilidad neta 2025

USD -35,3 M

Flujo operacional 2025

USD -23,3 M

Dividendos y splits

Último split1 por 20 (15 sept 2025)

BDSX hizo una agrupación de acciones (split inverso) de 1:20 el 15 de septiembre de 2025: cada 20 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

Noticias

Zacks Investment Research 6 nov
Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?
In a comparison of two oncology-focused healthcare companies, Champions Oncology (CSBR) is recommended as the better buy over Biodesix (BDSX). While BDSX has surged 156.7% over the past year, CSBR offers more attractive valuation metrics and better risk-reward positioning. CSBR benefits from strong demand for oncology research services, expanding data licensing opportunities, and radiopharmaceutical development initiatives. BDSX shows promise through lung diagnostic test adoption and operational improvements, but trades at a higher valuation with less upside potential.
Zacks Investment Research 4 nov
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics reported a quarterly loss of $0.16 per share, missing consensus estimates of $0.14, with revenues of $0.04 million falling 47.5% short of expectations. The stock has declined 34.6% year-to-date versus the S&P 500's 10.6% gain. The company holds a Zacks Rank #3 (Hold) rating and is expected to perform in line with the market.
GlobeNewswire Inc. 4 nov
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will present at two upcoming investor conferences in November 2026. The company will participate in a fireside chat and 1x1 meetings at the UBS Global Healthcare Conference on November 10 in Palm Beach Gardens, FL, and 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 17 in New York, NY. Presentations will be webcast live on the company's investor relations website.
Zacks Investment Research 29 oct
All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy
Biodesix, Inc. (BDSX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting an upward trend in earnings estimates over the past three months with a 7.8% increase in consensus estimates. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals and institutional investor buying pressure.
GlobeNewswire Inc. 19 oct
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases.

Regístrate para leer las noticias

Preguntas frecuentes sobre BDSX

¿Cómo invertir en BDSX desde Chile?

Crea tu cuenta en Racional en minutos, deposita desde CLP 5.000, busca BDSX y compra en dólares. No pagas comisión por transacción y puedes hacerlo desde la app o la web.

¿Cuál es el precio de BDSX hoy?

Al 15 de noviembre de 2026, BDSX cotiza a USD 9,95. En Racional puedes comprar fracciones, así que no necesitas pagar el precio de una acción completa.

¿Cuánto dinero necesito para invertir en BDSX?

Puedes empezar con CLP 5.000. Como Racional permite comprar fracciones de BDSX, inviertes el monto que quieras aunque sea menor al precio de una acción.

¿Qué es BDSX?

BDSX es la acción de Biodesix, Inc. Common Stock. Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

¿Cuánto ha rentado BDSX?

Al 15 de noviembre de 2026, BDSX registra +25,89% en el último año y +53,95% en lo que va del año. La rentabilidad pasada no garantiza resultados futuros.

¿Qué significa el split inverso de BDSX?

¿Cuánto cuesta invertir en BDSX con Racional?

Racional no cobra comisión por transacción ni por mantención en Stocks. La compra de dólares tiene un tipo de cambio de máximo 0,99%, que baja a 0,49% con el plan Pro.

¿Es seguro invertir en BDSX con Racional?

Tus inversiones en BDSX quedan en custodia de DriveWealth, broker regulado en EE.UU. por FINRA y protegido por SIPC. Racional está inscrita en la CMF.